Table 4 The association of anticoagulant drugs with VAF
From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure
Author | Design | N (Control) | Exposure Timing | Outcome (duration) | VAF development | Number of Bleeding events (Control) |
|---|---|---|---|---|---|---|
Crowther et al [74] | Placebo-controlled | 107 (51) | Warfarin Low-dose (INR 1.4–1.9) Post | Time to AVG failure | Equivalent risk (199 vs. 83 days, NS) | 0 (6) P = 0.03 |
Bhomi et al [73] | Placebo-controlled | 50 (25) | Heparin 5000 IU i.v Peri | Primary patency rates of AVF (6 weeks) | Equivalent risk (96% vs. 92%, P = 0.46) | 0 (12) P < 0.01 |
D'Ayala et al [72] | Placebo-controlled | 115 (58) | Heparin 5000 IU i.v Peri | Primary patency rates of VA (30 days) | Equivalent risk (84% vs. 86%, P = 0.79) | 1 (13) P = 0.008 |